← Leaderboards
Gang Huang
Cincinnati Childrens Hosp Med Ctr
$4,401,757
Attributed
$7,671,561
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,671,561 · 5
By mechanism
R01$7,298,331 · 4
R21$373,230 · 1
Top collaborators
- Shujun Liu6 shared
- William W Tse4 shared
- Ying Liang3 shared
Most similar at Cincinnati Childrens Hosp Med Ctr
Same institution · by research overlap
- H Leighton Grimes$23,205,568
Others in their field
Top investigators on “Mouse Model”
- Dennis R. Burton · Scripps Research Institute$280,661,242
- David Heimbrook · Leidos Biomedical Research, Inc.$84,491,283
- Kc Kent Lloyd · University Of California At Davis$74,285,556
- Alan F Horwitz · University Of Virginia Charlottesville$73,668,592
- Stanley B Prusiner · University Of California San Francisco$61,905,394
- Ed Lein · Allen Institute$59,425,748
Research focus
Mouse ModelMolecularResponseProteinsLoss Of FunctionCellsSelf-RenewalPathway InteractionsGain Of FunctionNew Therapeutic TargetEpigenetic ProcessTransgenic MiceUp-RegulationGenesDisease ProgressionMediatingSignal TransductionLeukemiaCell GrowthGenetic TranscriptionMalignant NeoplasmsInflammationImmune ResponseImpairment
Grant awards (16)
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell$1,206,321
R01 · FY2025 · CA
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell$573,003
R01 · FY2024 · CA
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell$591,097
R01 · FY2023 · CA
Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells.$435,732
R01 · FY2023 · DK
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute Myelogenous Leukemia$646,651
R01 · FY2022 · CA
Role of an Aberrant N6-Methyladenosine-LncRNA Axis in the Development and Maintenance of Drug Resistance through Regulating the Leukemia Stem Cell$618,411
R01 · FY2022 · CA
Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells.$388,500
R01 · FY2022 · DK
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute Myelogenous Leukemia$681,866
R01 · FY2021 · CA
Mechanism of the short- and long-term effects of COVID-19-induced Alarmins on hematopoietic stem and progenitor cells.$401,750
R01 · FY2021 · DK
Role of the Hypoxia-Inducible Factor-1alpha in Myelodysplastic Syndromes$351,000
R01 · FY2019 · DK · contact PI
Role of the Hypoxia-Inducible Factor-1alpha in Myelodysplastic Syndromes$351,000
R01 · FY2018 · DK · contact PI
Role of the Hypoxia-Inducible Factor-1alpha in Myelodysplastic Syndromes$351,000
R01 · FY2017 · DK · contact PI
Role of the Hypoxia-Inducible Factor-1alpha in Myelodysplastic Syndromes$351,000
R01 · FY2016 · DK · contact PI
Role of the Hypoxia-Inducible Factor-1alpha in Myelodysplastic Syndromes$351,000
R01 · FY2015 · DK · contact PI
A Novel Epigenetic Circuit in Acute Leukemia$203,580
R21 · FY2015 · CA · contact PI
A Novel Epigenetic Circuit in Acute Leukemia$169,650
R21 · FY2014 · CA · contact PI